Natco Pharma Stock Screener | Share Price & Fundamental Analysis
NATCOPHARM
Pharmaceuticals
Share Price NSE
₹891.70
▲
3.40 (0.38%)
Share Price BSE
₹890.80
▲
2.10 (0.24%)
Track Natco Pharma share price live with TickJournal's free stock screener.
Analyze Natco Pharma share price history trends and compare 52-week high low
levels.
Calculate NATCOPHARM stock fair value using fundamental analysis and view live share price charts.
Determine Natco Pharma share intrinsic value and compare it with current NATCOPHARM share price.
Record your Natco Pharma trades in TickJournal's free trading journal and track your portfolio performance.
Natco Pharma Market Cap
₹15,971.23 Cr.
EPS (TTM)
₹105.26
Dividend Yield
0.67%
Debt to Equity
0.05
NATCOPHARM 52 Week High
₹1035.10
Natco Pharma 52 Week Low
₹746.50
Operating Margin
25.00%
Profit Margin
21.42%
NATCOPHARM Revenue (TTM)
₹705.00
EBITDA
₹217.00
Net Income
₹151.00
Total Assets
₹8,631.00
Total Equity
₹7,612.00
Natco Pharma Share Price History - Stock Screener Chart
Screen NATCOPHARM historical share price movements with interactive charts. Analyze price trends and patterns.
Natco Pharma Company Profile - Fundamental Screener
Screen Natco Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for NATCOPHARM shares.
Natco Pharma Limited is a vertically integrated pharmaceutical company specializing in the development, manufacturing, and marketing of Finished Dosage Formulations and Active Pharmaceutical Ingredients. The company focuses on niche therapeutic areas and complex products, selling in over 40 countries. Natco operates in the Pharmaceuticals and Agro chemicals segments, with nine...more
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
V C Nannapaneni
ISIN
INE987B01026
Website
https://www.natcopharma.co.in
Natco Pharma Balance Sheet Screener
Screen NATCOPHARM balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 8,631 | 6,906 | 5,657 | 5,109 | 4,792 | 4,588 | 4,303 | 3,715 | 2,318 | 1,822 |
| Current Assets | 5,270 | 4,024 | 3,000 | 2,497 | 2,337 | 2,326 | 2,347 | 2,131 | 1,087 | 837 |
| Fixed Assets | 2,698 | 2,491 | 2,427 | 2,312 | 2,023 | 1,584 | 1,227 | 1,019 | 833 | 710 |
| Liabilities | ||||||||||
| Total Liabilities | 8,631 | 6,906 | 5,657 | 5,109 | 4,792 | 4,588 | 4,303 | 3,715 | 2,318 | 1,822 |
| Current Liabilities | 75 | 80 | 101 | 135 | 143 | 118 | 83 | 47 | 38 | 28 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 7,612 | 5,853 | 4,874 | 4,264 | 4,123 | 3,785 | 3,491 | 3,076 | 1,653 | 1,301 |
| Share Capital | 36 | 36 | 37 | 37 | 37 | 36 | 37 | 37 | 35 | 35 |
| Reserves & Surplus | 7,571 | 5,817 | 4,837 | 4,227 | 4,085 | 3,737 | 3,453 | 3,035 | 1,614 | 1,261 |
Natco Pharma Income Statement Screener - Profit & Revenue Analysis
Screen Natco Pharma income statement and profit fundamentals.
Analyze NATCOPHARM quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Natco Pharma share price evaluation.
| Item | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept | 2022-Jun |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 705 | 1,463 | 1,391 | 1,287 | 651 | 1,435 | 1,411 | 1,110 | 796 | 1,061 | 1,160 | 927 | 513 | 453 | 919 |
| Expenses | 489 | 784 | 758 | 673 | 436 | 567 | 558 | 571 | 491 | 573 | 613 | 559 | 387 | 337 | 489 |
| EBITDA | 217 | 679 | 633 | 614 | 215 | 868 | 853 | 539 | 305 | 487 | 548 | 368 | 127 | 116 | 430 |
| Operating Profit % | 25.00% | 42.00% | 43.00% | 45.00% | 8.00% | 59.00% | 59.00% | 47.00% | 35.00% | 44.00% | 46.00% | 38.00% | 22.00% | 22.00% | 45.00% |
| Depreciation | 46 | 52 | 58 | 98 | 47 | 46 | 44 | 56 | 44 | 44 | 44 | 41 | 42 | 42 | 40 |
| Interest | 10 | 13 | 3 | 10 | 4 | 4 | 5 | 6 | 5 | 4 | 4 | 3 | 4 | 4 | 4 |
| Profit Before Tax | 161 | 614 | 572 | 506 | 164 | 818 | 804 | 478 | 256 | 440 | 500 | 324 | 81 | 70 | 386 |
| Tax | 10 | 96 | 92 | 100 | 31 | 142 | 135 | 91 | 44 | 71 | 80 | 49 | 19 | 14 | 65 |
| Net Profit | 151 | 518 | 480 | 406 | 132 | 677 | 669 | 386 | 213 | 369 | 420 | 276 | 62 | 57 | 320 |
| EPS | 8.46 | 28.94 | 26.84 | 22.70 | 7.43 | 37.81 | 37.32 | 21.56 | 11.88 | 20.60 | 23.26 | 15.11 | 3.41 | 3.11 | 22.55 |
Natco Pharma Cash Flow Screener - Liquidity Fundamentals
Screen NATCOPHARM cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 1,697 | 1,212 | 849 | 47 | 299 | 417 | 669 | 464 | 346 | 112 |
| Investing Activities | -1,437 | -1,026 | -465 | 4 | -107 | -175 | -611 | -1,116 | -299 | -176 |
| Financing Activities | -211 | -247 | -363 | 35 | -186 | -251 | -51 | 651 | -48 | 154 |
| Net Cash Flow | 50 | -62 | 21 | 85 | 6 | -9 | 7 | -2 | -1 | 90 |
Natco Pharma Shareholding Pattern Screener
See Natco Pharma shareholding pattern with promoter, FII, and DII holdings.
Check Natco Pharma promoter holding and ownership changes for NATCOPHARM on TickJournal.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 49.56% | 49.56% | 49.48% | 49.48% | 49.71% | 49.71% | 49.62% | 49.62% |
| FII Holding | 17.49% | 15.51% | 14.09% | 15.16% | 16.14% | 17.45% | 17.51% | 17.94% |
| DII Holding | 5.65% | 5.82% | 5.87% | 5.39% | 9.70% | 7.87% | 6.75% | 5.57% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 23.68% | 25.22% | 25.84% | 25.38% | 20.60% | 21.59% | 22.60% | 23.34% |
| Other Holding | 3.61% | 3.89% | 4.72% | 4.58% | 3.85% | 3.39% | 3.52% | 3.53% |
| Shareholder Count | 405,222 | 429,434 | 419,699 | 424,167 | 228,467 | 251,485 | 302,944 | 345,332 |
Natco Pharma Share Dividend Screener - Share Yield Analysis
Check Natco Pharma dividend history with payout and yield data.
View Natco Pharma dividend details including ex-dates and amounts for NATCOPHARM stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹6.00 | 0.67% |
| 2024-March | ₹9.50 | 1.19% |
| 2023-March | ₹5.50 | 0.58% |
| 2022-March | ₹4.50 | 0.81% |
| 2021-March | ₹5.25 | 0.69% |
| 2020-March | ₹6.75 | 0.82% |
| 2019-March | ₹6.25 | 1.24% |
| 2018-March | ₹8.25 | 1.44% |
| 2017-March | ₹6.75 | 0.90% |
Natco Pharma Stock Index Membership
See which indices include Natco Pharma stock.
Check NATCOPHARM index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Natco Pharma Market Events Screener - Corporate Actions
Get Natco Pharma corporate actions including splits, bonuses, and buybacks.
Check Natco Pharma stock events that may affect NATCOPHARM share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | -3.48% | ||
| Annual General Meeting | NA | -0.11% | ||
| Annual General Meeting | NA | -1.94% | ||
| 2026-02-18 | 2026-02-18 | Dividend | ₹ 1.50 /share | 3.98% |
| 2026-02-12 | 2026-02-12 | Quarterly Result Announcement | NA | 4.49% |
| 2025-11-20 | 2025-11-20 | Dividend | ₹ 1.50 /share | 0.48% |
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | 3.21% |
| 2025-08-19 | 2025-08-19 | Dividend | ₹ 2.00 /share | -2.87% |
| 2025-08-12 | 2025-08-12 | Quarterly Result Announcement | NA | -2.84% |
| 2025-05-28 | 2025-05-28 | Quarterly Result Announcement | NA | 8.46% |
| 2025-02-18 | 2025-02-18 | Dividend | ₹ 1.50 /share | -29.89% |
| 2025-02-12 | 2025-02-12 | Quarterly Result Announcement | NA | 5.63% |
| 2024-11-27 | 2024-11-27 | Dividend | ₹ 1.50 /share | -2.91% |
| 2024-11-12 | 2024-11-12 | Quarterly Result Announcement | NA | 8.04% |
| 2024-08-23 | 2024-08-23 | Dividend | ₹ 3.00 /share | 7.67% |
Natco Pharma Competitors Screener - Peer Comparison
Screen NATCOPHARM competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 413,741 | 37.53 | 54,729 | 9.71% | 10,980 | 58.16 |
| Divis Laboratories | 167,006 | 67.40 | 9,712 | 18.67% | 2,191 | 53.89 |
| Torrent Pharmaceuticals | 143,558 | 62.90 | 11,539 | 6.99% | 1,911 | 66.58 |
| Cipla | 108,330 | 23.68 | 28,410 | 7.12% | 5,291 | 43.41 |
| Dr Reddys Laboratories | 106,866 | 19.34 | 33,741 | 16.73% | 5,725 | 60.10 |
| Lupin | 101,382 | 21.81 | 22,910 | 13.74% | 3,306 | 57.52 |
| Zydus Life Science | 90,637 | 18.06 | 23,511 | 18.55% | 4,615 | 49.52 |
| Mankind Pharma | 83,564 | 46.65 | 12,744 | 20.90% | 2,007 | 38.95 |
| Aurobindo Pharma | 67,303 | 19.60 | 32,346 | 9.43% | 3,484 | 47.48 |
| Alkem Laboratories | 64,469 | 26.53 | 13,458 | 3.70% | 2,216 | 37.57 |
Natco Pharma Company Announcements - News Screener
Screen NATCOPHARM latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| Announcement under Regulation 30 (LODR)-Newspaper Publication | View | |
| 2026-02-21 | Shareholder Meeting / Postal Ballot-Notice of Postal Ballot | View |
| 2026-02-19 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2026-02-15 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2026-02-14 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2026-02-14 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2026-02-13 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2026-02-13 | Corporate Action-Board approves Dividend | View |
| 2026-02-13 | Announcement under Regulation 30 (LODR)-Meeting Updates | View |
| 2026-02-13 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2026-02-13 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2026-02-13 | Un Audited Financial Results For The Quarter Ending 31St December 2025 | View |
| 2026-02-13 | Board Meeting Outcome for Out Come Of Board Meeting | View |
| 2026-02-03 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2026-02-03 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2026-02-02 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2026-01-30 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2026-01-28 | Board Meeting Intimation for Considering The Unaudited Financial Results For The Quarter And Period Ended 31St December 2025 And Declaration Of 3Rd Interim Dividend If Any For FY 2025-26 | View |
| 2026-01-07 | Clarification | View |
| 2026-01-07 | Clarification sought from Natco Pharma Ltd | - |